ABVX
AbivaxยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
ABVX Profile
Abivax Sa
A biotechnology company focused on harnessing the body's natural regulatory mechanisms to modulate the clinical stages of chronic inflammatory diseases
Biological Technology
12/04/2013
10/20/2023
NASDAQ Stock Exchange
69
12-31
Depository Receipts (Ordinary Shares)
7-11 boulevard Haussmann, 75009 Paris, France
--
Abivax Sa was incorporated on December 4, 2013 under the laws of France. The company is a clinical-stage biotechnology company focused on developing therapies that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is currently evaluating the lead drug candidate, Oberfazmod, in a Phase 3 clinical trial for the treatment of moderate-to-severe active ulcerative colitis in adults.
